Молекулярно-генетические маркеры при колоректальном раке

Молекулярно-генетические маркеры при колоректальном раке

Автор: Телышева Е.Н., Новикова Е.И., Снигирева Г.П.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Молекулярная медицина

Статья в выпуске: 3 т.19, 2019 года.

Бесплатный доступ

В статье представлен анализ и систематизация информации о молекулярно-генетических маркерах, имеющих первостепенное значение для выбора оптимальной тактики ведения больных колоректальным раком, а именно для повышения эффективности противоопухолевой терапии и прогноза заболевания.

Колоректальный рак, молекулярно-генетические маркеры, таргетная терапия, персонифицированная медицина

Короткий адрес: https://sciup.org/149132108

IDR: 149132108

Список литературы Молекулярно-генетические маркеры при колоректальном раке

  • Кит И., Водолажский Д. И. Молекулярная биология колоректального рака в клинической практике. Молекулярная биология. 2015. Т. 49. № 4. С. 531-540.
  • Федянин М. Ю., Гладков О. А., Гордеев С. С. и др. Практические рекомендации по лекарственному лечению рака ободочной кишки и ректосигмоидного соединения. RUSSCO. Злокачественные опухоли. 2018. Т. 8. № 3. 10.18 027 / 2224-5057-2018- 8-3s2-289-324. DOI: 10.18027/2224-5057-2018-8-3s2-289-324
  • Цуканов А.С., Шубин В.П., Кузьминов М.Х., и др. Дифференциальный диагноз MutYHассоциированного полипоза и спорадических полипов толстой кишки. Рос журн гастроэнетерол гепатол колопроктол 2018; 28(6), 51-57.
  • Abeloff M. D. Clinical Oncology. Sutton. UK.Churchill Livingstone. 1995.
  • Amatu A., Sartore-Bianchi A., Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016. V. 1. No. 9. e000023.
  • Armaghany T., Wilson J. D., Chu Q., Mills G. Genetic Alterations in Colorectal Cancer. Gastrointest Cancer Res. 2012. V. 5. No. 1. P. 19-27.
  • Arnold M., Sierra M.S., Laversanne M. et al. Global patterns and trends in colorectal cancer incidence and mortality. 2017. Gut. V. 66. No. 4. P. 683-691.
  • Benson A.B., Venook A.P., Al-Hawary M.M., et al. NCCN Guidelines Version 2.2018. Colon Cancer. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018. V. 16. No. 4. P. 359-369.
  • DOI: 10.6004/jnccn.2018.0021
  • Bertotti A., Migliardi G., Galimi F., et al. A molecularly annotated platform of patientderived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011. V. 1. No. 6. P. 508-523.
  • Bittoni A., Sotte V., Meletani T. et al. Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives. J Cancer Metastasis Treat. 2018. V. 4. No. 55.
  • DOI: 10.20517/2394-4722.2018.37
  • Cancer Stat Facts: Colorectal Cancer. Available Online: https://seer.cancer.gov/stat.facts/html/colorect.html (accessed on 30 November 2018)
  • Cathomas G. PIK3CA in colorectal cancer. Front Oncol. 2014. V. 4. P. 35.
  • DOI: 10.3389/fonc.2014.00035
  • Conlin A., Smith G., Carey F.A. et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005. V. 54. No. 9. P. 1283-1286.
  • DOI: 10.1136/gut.2005.066514
  • Créancier L., Vandenberghe I., Gomes B., et al. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Cancer Lett. 2015. V. 365. No. 107-111.
  • Di Popolo A., Memoli A., Apicella A. et al. IGF-II/IGF-I receptor pathway upregulate COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene. 2000. V. 19. P. 5517-5524.
  • DOI: 10.1038/sj.onc.1203952
  • Domingo E., Church D.N., Sieber O., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013. V. 31, No. 34. P. 4297-4305.
  • Duraturo F., Liccardo R., De Rosa M., Izzo P. Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges. Oncology letters. 2019. V. 17. No. 3. P. 3048-3054.
  • DOI: 10.3892/ol.2019.9945
  • Garde Noguera J., Jantus-Lewintre E., Gil-Raga M., et al. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Mol Clin Oncol. 2017. V. 6. No. 3. P. 403-408. Epub 2017 Feb 3.
  • DOI: 10.3892/mco.2017.1149
  • Geiersbach K.B., Samowitz W.S. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011. V. 135. No. 10. P. 1269-1277.
  • Goswami R.S., Patel K.P., Singh R.R. et al. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015. V. 21. No. 11. P. 2644-2651. Epub 2015/02/20. 10.1158/1078-0432.CCR-14-2391 PMID: 25695693.
  • DOI: 10.1158/1078-0432.CCR-14-2391PMID
  • Gray R.T., Cantwell M.M., Coleman H.G., et al. Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study. Clin Transl Gastroenterol. 2017. V. 8. No. 4. e91.
  • DOI: 10.1038/ctg.2017.18
  • Hamada T., Nowak J.A., Ogino S. PIK3CA mutation and colorectal cancer precision medicine. Oncotarget. 2017. V. 8. No. 14. P. 22305-22306.
  • Hegde M., Ferber M., Mao R., et al. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med. 2014. V. 16. No. 1.
  • DOI: 10.1038/gim.2013.166
  • Heidelberger C., Chaudhuri N.K., Danneberg P., et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature. 1957. V. 179. P. 663-666.
  • Jauhri M., Bhatnagar A., Gupta S., et al. Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing. Med Oncol. 2016. V. 33. No. P. 106. Epub 2016/08/29. 10.1007/s12032-016-0820-2 PMID: 27568332
  • DOI: 10.1007/s12032-016-0820-2PMID
  • Karapetis C.S., Jonker D., Daneshmand M., et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014. V. 20. No. 3. P. 744-753.
  • Kavuri S.M., Jain N., Galimi F., et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015. V. 5. No. 8. P. 832-841.
  • Langlois M.J., Bergeron S., Bernatchez G., et al. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS One. 2010. V. 5. No. 12. e15742.
  • DOI: 10.1371/journal.pone.0015742
  • Li X., Liu B., Xiao J., et al. Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer. J Gastrointest Surg. 2011. V. 15. No. 11. P. 2001-2010. Epub 2011/07/26. 10.1007/s11605-011-1627-2 PMID: 21786062
  • DOI: 10.1007/s11605-011-1627-2PMID
  • Malapelle U., Pisapia P., Sgariglia R., et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol. 2016. V.69. No. 9. P. 767-771. Epub 2016/01/23.
  • DOI: 10.1136/jclinpath-2015-203403
  • Martin-Zanca D., Hughes S.H., Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986. V. 319. No. 6056. P. 743-748.
  • Meyer L.A., Broaddus R.R., Lu K.H. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009. V. 16. No. 1. P. 14-22.
  • Ogino S., Kawasaki T., Kirkner G.J., et al. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007. V. 56. No. 11. P. 1564-1571.
  • Paleari L., Puntoni M., Clavarezza M., et al. PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. a systematic review and meta-analysis of epidemiological studies. Clin Oncol. (R Coll Radiol). 2016. V. 28. No. 5. P. 317-326.
  • DOI: 10.1016/j.clon.2015.11.008
  • Parsons D.W., Wang T.L., Samuels Y., et al. Colorectal cancer: mutations in a signalling pathway. Nature. 2005. V. 436. No. 7052. P. 792.
  • Prenen H., De Schutter J., Jacobs B., et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009. V. 15. No. 9. P. 3184-3188.
  • Razis E., Briasoulis E., Vrettou E., et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer. 2008. V. 8. P. 234.
  • Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004. V. 304. No. 5670. P. 554.
  • Sarshekeh A. M., Advani S., Overman J. M., et al. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE. 2017. V. 12. No. 5. e0173345. 10.1371/journal.pone.0173345. eCollection.
  • DOI: 10.1371/journal.pone.0173345.eCollection
  • Sartore-Bianchi A., Ardini E., Bosotti R., et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Inst. 2015. V. 108. No. 1. djv306.
  • Sartore-Bianchi A., Martini M., Molinari F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009. V. 69. No. 5. P. 1851-1857.
  • Sartore-Bianchi A., Trusolino L., Martino C., et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, openlabel, phase 2 trial. Lancet Oncol. 2016. V. 17. No. 6. P. 738-746.
  • Siena S., Sartore-Bianchi A., Lonardi S., et al. Trastuzumab and lapatinib in HER2amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. J Clin Oncol. 2015. V. 3 (15 Suppl). abstr 3508.
  • Therkildsen C., Bergmann T.K., Henrichsen-Schnack T. et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA и PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. J Acta Oncologica. 2014. P. 852-864.
  • DOI: 10.3109/0284186X.2014.895036
  • Tian S., Simon I., Moreno V., et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013. V. 62. No. 4. P. 540-549.
  • Tie J., Lipton L., Desai J. et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011. V. 17. No. 5. P. 1122-1130.
  • Van Cutsem E., Cervantes A., Adam R., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016. V. 27. No. 8. P. 1386-1422.
  • DOI: 10.1093/annonc/mdw235
  • Varghese M. A., Saltz B. L. BRAF mutation as a biomarker in colorectal cancer. Advances in Genomics and Genetics. 2015. P. 347-353.
  • Walther A., Johnstone E., Swanton C. et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009. V. 9. No. 7. P. 489-499.
  • Wang Q., Shi Y.L., Zhou K., et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018. V. 9. No. 7. 10.1038/s41419- 018-0776-6.
  • DOI: 10.1038/s41419-018-0776-6
  • Zhang B., Zhang B., Chen X., et al. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer. 2014. V. 110. No. 4. P. 946-957. Epub 2014/01/05. 10.1038/bjc.2013.789 PMID: 24384683.
  • DOI: 10.1038/bjc.2013.789PMID
Еще
Статья научная
SciUp 2024 © 2024 ©